Structure Therapeutics (GPCR) Competitors $18.90 -0.05 (-0.26%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$18.88 -0.02 (-0.11%) As of 04/15/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. OGN, ZLAB, ACLX, RNA, RARE, AKRO, MOR, SWTX, PTGX, and CPRXShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Organon & Co. (OGN), Zai Lab (ZLAB), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Organon & Co. Zai Lab Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Akero Therapeutics MorphoSys SpringWorks Therapeutics Protagonist Therapeutics Catalyst Pharmaceuticals Organon & Co. (NYSE:OGN) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Do analysts prefer OGN or GPCR? Organon & Co. currently has a consensus target price of $20.60, suggesting a potential upside of 86.17%. Structure Therapeutics has a consensus target price of $81.29, suggesting a potential upside of 330.08%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, OGN or GPCR? Organon & Co. has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.45$864M$3.333.32Structure TherapeuticsN/AN/A-$89.62M-$0.79-23.92 Is OGN or GPCR more profitable? Organon & Co. has a net margin of 13.49% compared to Structure Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 431.62% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% Structure Therapeutics N/A -16.37%-15.68% Do institutionals and insiders hold more shares of OGN or GPCR? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in OGN or GPCR? Structure Therapeutics received 13 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 88.57% of users gave Structure Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes1833.33% Underperform Votes3666.67% Structure TherapeuticsOutperform Votes3188.57% Underperform Votes411.43% Does the media refer more to OGN or GPCR? In the previous week, Organon & Co. had 10 more articles in the media than Structure Therapeutics. MarketBeat recorded 21 mentions for Organon & Co. and 11 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.00 beat Organon & Co.'s score of 0.64 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk & volatility, OGN or GPCR? Organon & Co. has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its share price is 235% less volatile than the S&P 500. SummaryOrganon & Co. beats Structure Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-25.546.7921.7317.81Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book1.935.866.464.00Net Income-$89.62M$141.86M$3.20B$247.23M7 Day Performance23.77%4.50%2.85%1.45%1 Month Performance-10.21%-12.65%-8.55%-6.24%1 Year Performance-50.03%-11.06%10.46%0.60% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.5757 of 5 stars$18.90-0.3%$81.29+330.1%-49.8%$1.09BN/A-25.54136News CoverageOGNOrganon & Co.4.798 of 5 stars$12.54-3.9%$20.80+65.9%-37.5%$3.23B$6.40B3.7610,000Short Interest ↓ZLABZai Lab2.4929 of 5 stars$28.81-9.3%$47.37+64.4%+113.9%$3.16B$398.99M-10.401,950News CoverageGap DownHigh Trading VolumeACLXArcellx1.9881 of 5 stars$56.65-3.3%$110.67+95.4%+7.8%$3.11B$107.94M-79.7980News CoveragePositive NewsGap DownHigh Trading VolumeRNAAvidity Biosciences2.2721 of 5 stars$25.48-4.1%$66.69+161.7%+11.6%$3.06B$10.90M-8.85190Gap DownRAREUltragenyx Pharmaceutical4.5522 of 5 stars$32.14-0.9%$92.79+188.7%-17.6%$3.02B$560.23M-5.071,310Positive NewsAKROAkero Therapeutics4.3059 of 5 stars$35.97-2.1%$76.29+112.1%+75.3%$2.86BN/A-9.5930Gap DownHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.0634 of 5 stars$36.99-5.4%$73.20+97.9%-11.6%$2.77B$191.59M-10.63230Positive NewsHigh Trading VolumePTGXProtagonist Therapeutics3.8055 of 5 stars$43.21-2.8%$62.56+44.8%+76.6%$2.65B$434.43M16.24120Positive NewsCPRXCatalyst Pharmaceuticals4.6031 of 5 stars$21.81-5.5%$32.29+48.0%+50.9%$2.65B$491.73M18.4880Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Organon & Co. Alternatives Zai Lab Alternatives Arcellx Alternatives Avidity Biosciences Alternatives Ultragenyx Pharmaceutical Alternatives Akero Therapeutics Alternatives MorphoSys Alternatives SpringWorks Therapeutics Alternatives Protagonist Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GPCR Stock Free GPCR Stock Alerts